Author: Kamau Therapeutics

Kamau Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Nula-cel, a Gene-Corrected Stem Cell Therapy for Sickle Cell Disease

November 12, 2026
Kamau Therapeutics Announces First Multi-Patient Clinical Data Showing Precise Correction of the Sickle Cell Mutation and Restoration of Adult Hemoglobin

November 4, 2026

Kamau Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Nula-cel, a Gene-Corrected Stem Cell Therapy for Sickle Cell Disease